Albany Molecular Research, Inc. (AMRI) and The RNA Institute at the University at Albany have entered into a collaboration to advance the discovery and development of RNA-based therapeutics and research tools.
 
AMRI, a global contract research and manufacturing organization, provides a portfolio of products, services to help refine and implement cost-effective and scalable solutions for the pharmaceutical and life science industry, including RNA-based therapeutics. As the science of RNA-based therapies evolves from discovery to manufacturing, there is a need to engineer new technologies and platforms to efficiently assess these entities and implement GLP/GMP standards and quality assays.
 
Through the agreement, RNA Institute-developed research tools and quality control and assessment standards will be shared with AMRI to refine, validate, and link commercial partners to support client research and development. The collaboration aims to facilitate additional RNA Institute partnerships to advance the research and development of new analytical tools for RNA-based therapeutics.
 
“We are excited to work with UAlbany’s RNA Institute to focus on improving RNA-based therapeutics,” said Christopher Conway, senior vice president, Discovery & Development Services.  “We look forward to collaborating with the Institute’s scientists in this exciting new area to continue to improve and make available RNA research tools for the broader drug discovery and development community, with the goal to ultimately see these discoveries translate to patients in a clinical setting.”
 
“This agreement is a first-of-its-kind between an academic institute or center and a contract research organization,” said Dr. Paul Agris, Director, The RNA Institute. “The Institute, because of its unique mission of science-driven technology development, will provide RNA technology advancement, new assays and materials that AMRI will use in support of their drug and diagnostics discovery programs.”

Visit AMRI at Table133